The Global Gastroesophageal Reflux Disease Therapeutics Market size was estimated at USD 5,583.13 million in 2022 and expected to reach USD 5,854.19 million in 2023, at a CAGR 4.99% to reach USD 8,243.60 million by 2030.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Gastroesophageal Reflux Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Gastroesophageal Reflux Disease Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
Market Segmentation & Coverage:
This research report categorizes the Global Gastroesophageal Reflux Disease Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:- Based on Type, market is studied across Branded and Generics. The Branded is projected to witness significant market share during forecast period.
- Based on Drug Class, market is studied across Aminosalicylates, Anti-Diarrheal, Anti-Emetics, Biologics/Biosimilar, Digestive enzymes, H2 Antagonists, Laxatives, and Proton Pump Inhibitors. The Anti-Diarrheal is projected to witness significant market share during forecast period.
- Based on Application, market is studied across Crohn’s Disease, GERD, and Ulcerative Colitis. The GERD is projected to witness significant market share during forecast period.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.FPNV Positioning Matrix:
The FPNV Positioning Matrix is essential for assessing the Global Gastroesophageal Reflux Disease Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).Market Share Analysis:
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Gastroesophageal Reflux Disease Therapeutics Market, including Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co., Ltd, Eisai Co., Ltd., EndoStim, Inc., GlaxoSmithKline PLC, Jeil Pharmaceutical Co., Ltd., Novartis AG, Reckitt Benckiser Group PLC, SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceuticals Industries Limited.The report provides insights on the following pointers:
- Market Penetration: Provides comprehensive information on the market offered by the key players
- Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
- Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
- Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
- Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
- What is the market size and forecast of the Global Gastroesophageal Reflux Disease Therapeutics Market?
- What are the inhibiting factors and impact of COVID-19 shaping the Global Gastroesophageal Reflux Disease Therapeutics Market during the forecast period?
- Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastroesophageal Reflux Disease Therapeutics Market?
- What is the competitive strategic window for opportunities in the Global Gastroesophageal Reflux Disease Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Global Gastroesophageal Reflux Disease Therapeutics Market?
- What is the market share of the leading vendors in the Global Gastroesophageal Reflux Disease Therapeutics Market?
- What modes and strategic moves are considered suitable for entering the Global Gastroesophageal Reflux Disease Therapeutics Market?
Frequently Asked Questions about the Global Gastroesophageal Reflux Disease Therapeutics Market
What is the estimated value of the Global Gastroesophageal Reflux Disease Therapeutics Market?
What is the growth rate of the Global Gastroesophageal Reflux Disease Therapeutics Market?
What is the forecasted size of the Global Gastroesophageal Reflux Disease Therapeutics Market?
Who are the key companies in the Global Gastroesophageal Reflux Disease Therapeutics Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 245 |
| Published | May 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5583.13 Million |
| Forecasted Market Value ( USD | $ 8243.6 Million |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Gastroesophageal Reflux Disease Therapeutics Market, by Type
7. Gastroesophageal Reflux Disease Therapeutics Market, by Drug Class
8. Gastroesophageal Reflux Disease Therapeutics Market, by Application
9. Americas Gastroesophageal Reflux Disease Therapeutics Market
10. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market
11. Europe, Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market
12. Competitive Landscape
13. Company Usability Profiles
14. Appendix
List of Figures
List of Tables
Companies Mentioned
- Aurobindo Pharma Limited
- Cadila Pharmaceuticals Limited
- CHEPLAPHARM Arzneimittel GmbH
- Daewoong Pharmaceutical Co., Ltd
- Eisai Co., Ltd.
- EndoStim, Inc.
- GlaxoSmithKline PLC
- Jeil Pharmaceutical Co., Ltd.
- Novartis AG
- Reckitt Benckiser Group PLC
- SFJ Pharmaceuticals Group
- SRS Life Sciences Pte. Ltd.
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceuticals Industries Limited
Methodology
LOADING...
